Skip to main content
. Author manuscript; available in PMC: 2014 Jan 26.
Published in final edited form as: Clin Cancer Res. 2012 Aug 14;18(19):5163–5171. doi: 10.1158/1078-0432.CCR-12-0313

Figure 1. Therapeutic Targets in AML.

Figure 1

Therapy may be directed against signals generated by growth factor receptors (IL3-R, FLT3) by direct kinase inhibition, by inhibition of downstream signaling (MEK), (PI3K/AKT/mTOR) or by interference with the HSP90 chaperone protein. Additional targets on the horizon include migration/stromal interactions (SDF-1/CXCR4), anti-apoptotic molecules (BCL2), or aberrant DNA methylation and histone methylation. The leukemia cell surface may be targeted by anti-CD33 antibodies, other monoclonal antibodies or tumor vaccines.